Sentences with phrase «placental malaria»

Both studies are ongoing and the full data analyses, including results from samples collected after pregnancy and placental malaria, are expected to be completed by Mid-2017.

The Laboratory of Malaria Immunology and Vaccinology (LMIV), U.S. National Institute of Allergy and Infectious Diseases (NIAID) has established a nonhuman primate model of placental malaria that for the first time reproduces all the features of P. falciparum malaria in pregnant women.

In a second study, the goal is to assess the Aotus model of P. falciparum placental malaria as a platform for assessing placental malaria vaccine candidates.

The PRIMVAC placental malaria vaccine candidate has been shown to be stable for 18 months, therefore the expiry date of the clinical lot could be extended.

The overall objective of PlacID is to validate the non-human primate animal model developed at NIAID - LMIV for the evaluation of the placental malaria vaccine candidates and to assess it as a platform for testing placental malaria vaccine candidates prior to human testing.

If validated, the model will accelerate placental malaria vaccine development by facilitating quicker down - selection of vaccine candidates and providing safety data in pregnant primates at pre-clinical stage.

There are no licensed vaccines for placental malaria and current strategies to prevent the disease rely on vector eradication (e.g. using chemically - treated bed nets, indoor residual spraying) combined with the intermittent administration of antimalarial drugs.

Nicola Viebig presented on behalf of Patrick Duffy and the team the placental malaria animal model (PlacID) project.

The two projects PRIMALVAC and PAMCPH / PlacMalVac aim at the development of a VAR2CSA based vaccine that could be administered to nulligravid women (before first pregnancy) thus inducing a state of protective immunity that is comparable to multigravid women and efficiently prevents subsequent episodes of placental malaria.

Only women who have previously suffered from placental malaria develop substantial levels of protective antibodies that prevent the adhesion of red blood cells to placental CSA.

The nets also reduced cases of placental malaria among pregnant women by 23 %, and 28 % fewer had low - birth - weight babies.

Not exact matches

Infections such as malaria can impair that pathway, restricting placental vascular development.

In their paper entitled, «Malaria in pregnancy alters L - arginine bioavailability and placental vascular development,» Science Translational Medicine, 7 March 2018, Toronto General Research Institute (TGRI) and University of Toronto researchers report that Malawian women with malaria in pregnancy had altered levels of L - arginine which were associated with poor birth ouMalaria in pregnancy alters L - arginine bioavailability and placental vascular development,» Science Translational Medicine, 7 March 2018, Toronto General Research Institute (TGRI) and University of Toronto researchers report that Malawian women with malaria in pregnancy had altered levels of L - arginine which were associated with poor birth oumalaria in pregnancy had altered levels of L - arginine which were associated with poor birth outcomes.